Stroke and Headache Headache and Stroke
|
|
- Clemence Cunningham
- 5 years ago
- Views:
Transcription
1 Stroke and Headache Headache and Stroke Hans-Christoph Diener Senior Professor of Clinical Neurosciences University Duisburg-Essen Tobias Kurth Institute of Public Health Charité Universitätsmedizin Berlin Germany
2 Conflict of Interest Statement (Headache) German Research Council German Ministry of Education and Reserach EU Addex Alder Allergan Almirall Amgen Astra-Zeneca Bayer BMS Böhringer-Ingelheim Chordate Coherex CoLucid Eisai Electrocore Endo Pharmac. GSK Janssen-Cilag J&J Labrys Lilly MAP Menarini Medtronic MSD Neuroscore Novartis Novo Nordisk Pfizer Sanofi-Aventis Schering Solvay St. Jude Medical Teva Weber & Weber Wyeth
3 Conflict of Interest Statement (Stroke) The speaker or his institution received financial support from the following bodies or companies: German Research Council German Ministry of Health German Ministry of Science and Technology European Union Bertelsmann Foundation Heinz-Nixdorf Foundation Abbott Allergan Achelios Actelion AstraZeneca Bayer Boehringer Ingelheim Brainsgate BristolMyersSquibb CoAxia Corimmun Covidien D-Pharm Daiichi-Sankyo Fresenius GlaxoSmithKline Jansen-Cilag Johnson&Johnson Lilly Lundbeck Medtroni Mindframe MSD Neurobiological Technologies Novo Nordisk Novartis Paion Pfizer Sanofi Schering Schering Plough Servier Solvay St. Jude Syngis Tacrelis Thrombogenics
4 Overview Headache in stroke Pathophysiology of headache in stroke Epidemiology of stroke and migraine Migraine and structural brain lesions Migraine and arterial dissection Migraine and PFO SMART Posterior reversible encephalopathy syndrome Stroke mimics Here is the summary and conclusion 4
5 Overview Headache in stroke Pathophysiology of headache in stroke Epidemiology of stroke and migraine Migraine and structural brain lesions Migraine and arterial dissection Migraine and PFO SMART Posterior reversible encephalopathy syndrome Stroke mimcs 5
6 Headache in Stroke 6
7 Headache in Stroke 7
8 Headache associated with ischemic stroke Presentation and course Onset abrupt or gradual More frequent in posterior circulation strokes More severe in basilar artery stroke Sentinel headache only in SAH Late onset associated with brain edema 8
9 Overview Headache in stroke Pathophysiology of headache in stroke Epidemiology of stroke and migraine Migraine and structural brain lesions Migraine and arterial dissection Migraine and PFO SMART Posterior reversible encephalopathy syndrome Stroke mimcs 9
10 Schlaganfall und Kopfschmerzen Lesions were summed 10
11 Schlaganfall und Kopfschmerzen Involvement of the central pain network 11
12 Overview Headache in stroke Pathophysiology of headache in stroke Epidemiology of stroke and migraine Migraine and structural brain lesions Migraine and arterial dissection Migraine and PFO SMART Posterior reversible encephalopathy syndrome Stroke mimcs 12
13 Epidemiologic evidence: migraine-stroke First description of migrainous infarct likely by Charcot and Féré ~1883 Several clinic- and population-based studies found an association between migraine and increased risk of ischemic stroke Consistent findings from cross-sectional, casecontrol, and cohort studies Particular increased risk for younger women (<45 years) Most studies found increased risk of stroke only among migraineurs with aura
14 Epidemiologic evidence: migraine-stroke, cont. Findings from prospective cohort studies: Atherosclerosis Risk in Communities Study (ARIC) included 12,409 men and women mostly aged >55* Migraine/headache assessed via interview Medical record validated strokes Women s Health Study (WHS) included 39,754 women aged >45 and free of cardiovascular disease ** Migraine/headache self-reported Medical record confirmed stroke * Stang et al. Neurology 2005; 64: ** Kurth et al. Neurology 2005; 64:1020-6
15 Relative Risk Epidemiologic evidence: migraine-stroke, cont. Association between migraine/headache and ischemic stroke 2,5 2,0 1,5 1,0 Migraine + aura Migraine - aura Non-migraine headache 0,5 0,0 ARIC* WHS** Risk of stroke increased in migraine with aura * Stang et al. Neurology 2005; 64: ** Kurth et al. Neurology 2005; 64:1020-6
16 Migraine and stroke: meta-analysis Case-control and cohort studies included 9 studies evaluated association between migraine and ischemic stroke from different source populations If studies uses same underlying source population, only longest follow-up or cohort design was selected Overall migraine associated with 70% increased risk of ischemic stroke (RR=1.73; 95% CI= ) Association only apparent among migraineurs with aura Schürks et al. BMJ 2009;339:b3914
17 Migraine and stroke: meta-analysis, cont. Association between migraine with and without aura and ischemic stroke Risk of stroke increased in migraine with aura Schürks et al. BMJ 2009;339:b3914
18 Relative Risk Migraine and stroke: meta-analysis subgroups Relative Risk of Ischemic Stroke Overall MA MO Women <45 + OC + Smoking Most important risk factors: oral contraception and smoking Schürks et al. BMJ 2009;339:b3914
19 Migraine and hemorrhagic stroke Migraine with aura increased the risk of hemorrhagic stroke RR = 2.31 ( ) Kurth et a. BMJ 2010;c3659
20 Relatives Risko Migraine and hemorrhagic stroke Adjusted Relative Risk 4,0 3,5 3,0 2,5 2,0 1,5 1,0 0,5 0,0 Hem. Stroke ICH SAH Fatal MA Migraine increases the risk of intracranial hemorrhage Kurth et a. BMJ 2010;c3659
21 Epidemiology Migraine is a risk factor for any vascular disease 21
22 Migraine and perioperative stroke Risk of stroke within 30 days of surgery (N= ) 22
23 Migraine and perioperative stroke Risk of perioperative ischemic stroke increased by 75% 23
24 CT and CT angiography 24
25 No increased risk of atherosclerosis in patients with migraine and stroke 25
26 Summary Migraine with aura is a risk factor for ischemic stroke Migraine is a risk factor for cerebral hemorrhage Migraine with aura is a risk factor for vascular diseases Migraine increases the risk of perioperative stroke Patients with migraine have more vascular risk factors (but not more atherosclerosis) Patients with migraine might have dysfunction of the endothelium 26
27 Migraine genetics 27
28 Migraine genetics The new gene loci code for vascular endothelium, CNS pain structures, GI tissue and smooth muscle 28
29 Overview Headache in stroke Pathophysiology of headache in stroke Epidemiology of stroke and migraine Migraine and structural brain lesions Migraine and arterial dissection Migraine and PFO SMART Posterior reversible encephalopathy syndrome Stroke mimcs 29
30 Migraine and structural brain lesions Several studies have linked migraine with increased load of white matter lesions and increase in infarctlike lesions in the posterior circulation The CAMERA study showed: Migraine associated with 7-fold increase in risk of infarctlike lesions in cerebellum with migraine frequency and among migraine with aura In women, migraine with aura doubled risk of deep WML No difference according to migraine aura status Reykjavik study showed: Migraine with aura in midlife increased infarct-like lesions the cerebellum in late-life by 60% Result only apparent among women (RR = 1.9)
31 % with High-DWML-load Deep WML in migraine patients The Dutch CAMERA general population MRI study 35,0 30,0 25,0 20,0 15,0 10,0 5,0 0, Quintiles of attack frequency Migraineurs (n=195) Controls (n=140) Effect attacka frequency in women < 50 yr 1 Controls 4,6 p<0.03 Migraine <1/month 7,8 p<0.005 Migraine >1/month Kruit MC, et al. JAMA 2004; 291:
32 Migraine, white matter lesions and silent brain infarcts 32
33 Migraine, white matter lesions and silent brain infarcts No increase in white matter lesions and silent brain infarcts in migraine with aura 33
34 Overview Headache in stroke Pathophysiology of headache in stroke Epidemiology of stroke and migraine Migraine and structural brain lesions Migraine and arterial dissection Migraine and PFO SMART Posterior reversible encephalopathy syndrome Stroke mimcs 34
35
36
37 Overview Headache in stroke Pathophysiology of headache in stroke Epidemiology of stroke and migraine Migraine and structural brain lesions Migraine and arterial dissection Migraine and PFO SMART Posterior reversible encephalopathy syndrome Stroke mimcs 37
38 Migraine with aure and patent foramen ovale (PFO) PFO occlusion not effective to prevent migraine with aura 38
39 Summary Conflicting data concerning white matter lesions and silent brain infarcts in migraine with aura Migraine is a risk factor for dissection PFO closure does not prevent migraine with aura 39
40 Overview Headache in stroke Pathophysiology of headache in stroke Epidemiology of stroke and migraine Migraine and structural brain lesions Migraine and arterial dissection Migraine and PFO SMART Posterior reversible encephalopathy syndrome Stroke mimcs 40
41 a Headache in combination with prolonged reversible neurological signs 41
42 Overview Headache in stroke Pathophysiology of headache in stroke Epidemiology of stroke and migraine Migraine and structural brain lesions Migraine and arterial dissection Migraine and PFO SMART Posterior reversible encephalopathy syndrome Stroke mimcs 42
43 a Headache frequent symptom 43
44 a Triggers or associations with PRES Autoimmune disorders Systemic LE TTP Scleroderma Crohn s disease Rheumatoid arthritis Immunosuppressive or cytotoxic drugs Ciclosporine Tacrolimus Antiangiogenic drugs Triggers or associations with PRES Renal failure Hypertensive crisis Low magnesium Pregnancy Headache frequent symptom 44
45 Overview Headache in stroke Pathophysiology of headache in stroke Epidemiology of stroke and migraine Migraine and structural brain lesions Migraine and arterial dissection Migraine and PFO SMART Posterior reversible encephalopathy syndrome Stroke mimics 45
46 a 46
47 Overview Headache in stroke Pathophysiology of headache in stroke Epidemiology of stroke and migraine Migraine and structural brain lesions Migraine and arterial dissection Migraine and PFO SMART Posterior reversible encephalopathy syndrome Stroke mimics 47
48 Thank you
Clinical Trials. Hans-Christoph Diener Senior Professor of Clinical Neuroscienes Medical Faculty University Duisburg-Essen Germany
Clinical Trials Hans-Christoph Diener Senior Professor of Clinical Neuroscienes Medical Faculty University Duisburg-Essen Germany Conflict of Interest Statement German Research Council German Ministry
More informationNew Aspects in the Diagnosis and Treatment of Atrial Fibrillation: Antithrombotic Therapy
New Aspects in the Diagnosis and Treatment of Atrial Fibrillation: Antithrombotic Therapy Hans-Christoph Diener Department of Neurology and Stroke Center University Hospital Essen Germany Conflict of Interest
More informationEditorial Team Conflict of Interest Statements
Editorial Team Conflict of Interest Statements Editor in Chief David Dodick Advisory board/consultant: Allergan, Amgen, Alder, Arteaus, Pfizer, Colucid, Merck, ENeura, NuPathe, Eli Lilly, Autonomic Technologies,
More informationMigraine and Stroke: What s the link? Christine Lay, MD, FAHS Associate Professor (Neurology) University of Toronto Director, Headache
Migraine and Stroke: What s the link? Christine Lay, MD, FAHS Associate Professor (Neurology) University of Toronto Director, Headache Disclosures Objectives Consultant Novartis, Aralez Research/educational
More informationPFO Closure for the Management of Migraine and Stroke
PFO Closure for the Management of Migraine and Stroke Sun U. Kwon Department of Neurology, Asan Medical Center, UUMC Contents PFO & Migraine PFO causes Migraine or Not? PFO closure for Migraine PFO & Stroke
More informationA.K. Gitt, F. Towae, C. Juenger, A. Papp, R. Zahn, U. Zeymer, J. Senges For the STAR-Study-Group Herzzentrum Ludwigshafen, Germany
Impact of Interventional Versus Conservative Approach on 5-Year-Mortality of Patients With Stable Angina and Documented Coronary Artery Disease in Clinical Practice: Results of the STAR-Registry A.K. Gitt,
More informationFunding Wellcome Trust, the National Institute of Health Research (NIHR) Biomedical Research Centre, Oxford.
Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials Peter M Rothwell, Ale Algra, Zhengming
More informationUpdate on clopidogrel and dual anti-platelet therapy: neurology
European Heart Journal Supplements (2006) 8 (Supplement G), G15 G19 doi:10.1093/eurheartj/sul049 Update on clopidogrel and dual anti-platelet therapy: neurology Hans-Christoph Diener Department of Neurology,
More informationIdentification of negative predictors of pain-free response to triptans: Analysis of the eletriptan database
doi:10.1111/j.1468-2982.2007.01457.x Identification of negative predictors of pain-free response to triptans: Analysis of the eletriptan database H-C Diener 1, DW Dodick 2, PJ Goadsby 3, RB Lipton 4, M
More information7 th Munich Vascular Conference
7 th Munich Vascular Conference Secondary prevention of major cardiovascular events in patients with CHD or PAD - What can we learn from EUCLID and COMPASS, evaluating Clopidogrel, Ticagrelor and Univ.-Prof.
More informationMigraine and Patent Foramen Ovale (PFO)
Migraine and Patent Foramen Ovale (PFO) Hans-Christoph Diener Senior Professor of Clinical Neurosciences Department of Neurology and Headache Center University Essen Topics Prevalence of PFO Is migraine
More informationDecision for fibrinolysis or primary PCI in the prehospital phase
Decision for fibrinolysis or primary PCI in the prehospital phase Nicolas Danchin, Hôpital Européen Georges Pompidou, Paris, France Disclosures Research grants: Astrazeneca, Eli-Lilly, GSK, Merck, Novartis,
More informationHome Time Is Extended in Patients With Ischemic Stroke Who Receive Thrombolytic Therapy A Validation Study of Home Time as an Outcome Measure
Home Time Is Extended in Patients With Ischemic Stroke Who Receive Thrombolytic Therapy A Validation Study of Home Time as an Outcome Measure Nishant K. Mishra, MBBS; Ashfaq Shuaib, MD; Patrick Lyden,
More informationNovel Anticoagulants : Bleeding and Bridging
Novel Anticoagulants : Bleeding and Bridging Michael D. Ezekowitz, MBChB, DPhil, FACC, FAHA, FRCP, MA Professor, Thomas Jefferson Medical School Director Atrial Fibrillation Research and Education The
More informationSubclinical atherosclerosis in CVD: Risk stratification & management Raul Santos, MD
Subclinical atherosclerosis in CVD: Risk stratification & management Raul Santos, MD Sao Paulo Medical School Sao Paolo, Brazil Subclinical atherosclerosis in CVD risk: Stratification & management Prof.
More informationEngage AF-TIMI 48. Edoxaban in AF: What can we expect? Cardiology Update John Camm. St. George s University of London United Kingdom
Cardiology Update 2013 N S N O N H O H N S1 pocket Aryl binding N site O O N H N Cl Engage AF-TIMI 48 Edoxaban in AF: What can we expect? John Camm St. George s University of London United Kingdom Advisor
More informationThe Global SYMPLICITY Registry: Safety and Effectiveness of Renal Artery Denervation In Real World Patients With Uncontrolled Hypertension
The Global SYMPLICITY Registry: Safety and Effectiveness of Renal Artery Denervation In Real World Patients With Uncontrolled Hypertension Michael Böhm, MD on behalf of the GSR Investigators March 30,
More informationWHICH ANTITHROMBOTIC REGIMEN? Action Study Group Institut de Cardiologie - Pitié-Salpêtrière Hospital Paris, France.
TAVI WITH ATRIAL FIBRILLATION: WHICH ANTITHROMBOTIC REGIMEN? G. MONTALESCOT (PARIS, FR) Action Study Group Institut de Cardiologie - Pitié-Salpêtrière Hospital Paris, France www.action-cœur.org Dr. Montalescot
More informationINTRACEREBRAL HAEMORRHAGE:
INTRACEREBRAL HAEMORRHAGE: WHAT IS THE CAUSE? Prof. Charlotte Cordonnier Head, Department of neurology & stroke centre Director, Lille haemorrhagic stroke research program Lille University Hospital France
More informationThe Universal Definition of Myocardial Infarction 3 rd revision, 2012
The Universal Definition of Myocardial Infarction 3 rd revision, 2012 Joseph S. Alpert, MD Professor of Medicine, University of Arizona College of Medicine, Tucson, AZ; Editor-in-Chief, American Journal
More informationIs There a Role For Pharmacokinetic/ Pharmacodynamics Guided Dosing For Novel Anticoagulants? Christopher Granger
Is There a Role For Pharmacokinetic/ Pharmacodynamics Guided Dosing For Novel Anticoagulants? Christopher Granger 1 Disclosures Research contracts: Armetheon, AstraZeneca, Bayer, Boehringer Ingelheim,
More informationTHE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES
THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES PUBLISHED AUGUST 2016 There is growing distrust of pharma in light of several recent and dramatic
More informationHow clinically important are the results of the large trials in hypertension?
How clinically important are the results of the large trials in hypertension? Stéphane LAURENT, MD, PhD, FESC Pharmacology Department and PARCC / INSERM U970 Hôpital Européen Georges Pompidou, Université
More informationNT-proBNP For The Detection of Silent Paroxysmal Atrial Fibrillation In Patients With Recent Cerebral Ischemia results from the Find-AF trial
NT-proBNP For The Detection of Silent Paroxysmal Atrial Fibrillation In Patients With Recent Cerebral Ischemia results from the Find-AF trial R. Wachter a, R. C. Lahno a, B. Haase a, M. Weber-Krüger a,
More informationThis e-reprint is distributed with the support of Bayer Pharma / Bayer Vital
http://neurology.thelancet.com Reprint Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF Graeme
More informationPERCUTANEOUS CLOSURE OF PATENT FORAMEN OVALE AND ATRIAL SEPTAL DEFECT: STATE OF THE ART AND A CRITICAL APPRAISAL
PERCUTANEOUS CLOSURE OF PATENT FORAMEN OVALE AND ATRIAL SEPTAL DEFECT: STATE OF THE ART AND A CRITICAL APPRAISAL Carmelo Cernigliaro Clinica San Gaudenzio Novara Eco 2D e 3D Eco Transesofageo Large shunt
More informationClinical and Economic Value of Rivaroxaban in Coronary Artery Disease
CHRISTOPHER B. GRANGER, MD Professor of Medicine Division of Cardiology, Department of Medicine; Director, Cardiac Care Unit Duke University Medical Center, Durham, NC Clinical and Economic Value of Rivaroxaban
More informationThe Epidemiology of Stroke and Vascular Risk Factors in Cognitive Aging
The Epidemiology of Stroke and Vascular Risk Factors in Cognitive Aging REBECCA F. GOTTESMAN, MD PHD ASSOCIATE PROFESSOR OF NEUROLOGY AND EPIDEMIOLOGY JOHNS HOPKINS UNIVERSITY OCTOBER 20, 2014 Outline
More informationDisclosures. Dr. Scirica has also served as a consultant for Lexicon, Arena, Gilead, and Eisai.
Disclosures Benjamin M. Scirica, MD, MPH, is employed by the TIMI Study Group, which has received research grants from Abbott, AstraZeneca, Amgen, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb,
More informationPatent Foramen Ovale and Cryptogenic Stroke: Do We Finally Have Closure? Christopher Streib, MD, MS
Patent Foramen Ovale and Cryptogenic Stroke: Do We Finally Have Closure? Christopher Streib, MD, MS 11-8-18 Outline 1. Background 2. Anatomy of patent foramen ovale (PFO) 3. Relationship between PFO and
More informationin patients with diabetes, nephropathy and/or chronic kidney disease Summary of recommendations July 2017
Association of British Clinical Diabetologists (ABCD) and Renal Association clinical guidelines: Hypertension management and reninangiotensin-aldosterone system blockade in patients with diabetes, nephropathy
More informationAntithrombotic therapy in the ACS patient with atrial fibrillation
Antithrombotic therapy in the ACS patient with atrial fibrillation Kurt Huber, MD, FESC, FACC, FAHA 3 rd Medical Department Cardiology & Emergency Medicine Wilhelminenhospital Vienna, Austria Great Minds,
More informationShould hypertensive disorders of pregnancy be considered as a prehypertension state?
February 2018 Should hypertensive disorders of pregnancy be considered as a prehypertension state? Pr. Jacques Blacher Paris-Descartes University ; AP-HP ; Unité HTA, prévention et thérapeutique cardio-vasculaires,
More informationJ. Michael Gaziano, M.D., M.P.H. European Society of Cardiology August 26 th 2018
ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events): A Study to Assess the Efficacy and Safety of Aspirin in Patients at Moderate Risk of Cardiovascular Disease J. Michael Gaziano, M.D., M.P.H.
More informationNOAC trials for AF: A review
NOAC trials for AF: A review Chern-En Chiang, MD, PhD, FACC, FESC General Clinical Research Center Division of Cardiology Taipei Veterans General Hospital National Yang-Ming University Taipei, Taiwan Presenter
More informationNOACs Update PD Dr. Jan Steffel Leitender Arzt, Klinik für Kardiologie Co-Leiter Rhythmologie Universitätsspital Zürich
NOACs Update 2016 PD Dr. Jan Steffel Leitender Arzt, Klinik für Kardiologie Co-Leiter Rhythmologie Universitätsspital Zürich Conflict of Interest Statement o o o o Consulting: Amgen, Astra Zeneca, AtriCure,
More informationCEREBRO VASCULAR ACCIDENTS
CEREBRO VASCULAR S MICHAEL OPONG-KUSI, DO MBA MORTON CLINIC, TULSA, OK, USA 8/9/2012 1 Cerebrovascular Accident Third Leading cause of deaths (USA) 750,000 strokes in USA per year. 150,000 deaths in USA
More informationDevelopment and validation of a pharmacy migraine questionnaire to assess suitability for treatment with a triptan
J Headache Pain (2008) 9:359 365 DOI 10.1007/s10194-008-0070-6 ORIGINAL Development and validation of a pharmacy migraine questionnaire to assess suitability for treatment with a triptan Hans-Christoph
More informationcontroversies in anticoagulation: optimizing outcome for atrial fibrillation
controversies in anticoagulation: optimizing outcome for atrial fibrillation SUNDAY, NOVEMBER 13, 2016 WESTIN HOTEL NEW ORLEANS CANAL PLACE COLLABORATE INVESTIGATE EDUCATE PROVIDING PERSPECTIVE: CURRENT
More informationPer cent of patients with chronic migraine who responded per onabotulinumtoxina treatment cycle: PREEMPT
Migraine 1 Department of Neurology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA 2 Department of Neurology, Mayo Clinic Arizona, Phoenix, Arizona, USA 3 Department of Neurology and Neurological
More informationOvercoming the Risk-Treatment Paradox in Non-STE ACS: It s Time! Christopher Granger, MD
Overcoming the Risk-Treatment Paradox in Non-STE ACS: It s Time! Christopher Granger, MD Disclosures Research contracts: AstraZeneca, Bayer, Novartis, GSK, Sanofi-Aventis, BMS, Pfizer, The Medicines Company,
More informationWhy Treat Patent Forman Ovale
Why Treat Patent Forman Ovale Clifford J Kavinsky, MD, PHD Professor of Medicine and pediatrics Associate Director, Center for Congenital and Structural Heart Disease Rush University Medical Center Conclusions
More informationSUPPLEMENTARY DATA. Telediab Study Group :
Telediab Study Group : Guillaume Charpentier, MD, Department of Diabetes, Sud-Francilien Hospital, Corbeil-Essonnes, France Centre d Études et de Recherches pour l Intensification du Traitement du Diabète
More informationA Patient Unsuitable for VKA Treatment
Will Apixaban change practice in atrial fibrillation? A Patient Unsuitable for VKA Treatment Professor Yoseph Rozenman The E. Wolfson Medical Center Jerusalem June 2013 Disclosures I have the following
More informationPost Hoc Analysis of the PARADIGM Heart Failure Trial:
Post Hoc Analysis of the PARADIGM Heart Failure Trial: Pulse Pressure and Outcomes in Heart Failure with Reduced Ejection Fraction Chen-Huan Chen, M.D. Professor, Department of Medicine, National Yang-Ming
More informationnephropathy and/or chronic kidney disease Summary of recommendations
July 2017 Guidelines: Association of British Clinical Diabetologists (ABCD) and Renal Association clinical guidelines: Hypertension management and reninangiotensin-aldosterone system blockade in patients
More informationGlucose Control and Prevention of Cardiovascular Disease
Glucose Control and Prevention of Cardiovascular Disease Dr Peter A Senior BMedSci MBBS PhD FRCP(E) Associate Professor, Director Division of Endocrinology, University of Alberta Diabetes Update+, March
More informationEvidence grades for the recommendations
Association of British Clinical Diabetologists (ABCD) and Renal Association clinical guidelines: Hypertension management and renin-angiotensin-aldosterone system blockade in patients with diabetes, nephropathy
More informationANTIPAF Angiotensin II Antagonist in Paroxysmal Atrial Fibrillation Trial
European Society of Cardiology Hotline Stockholm - Zone K 31 st August 2010 Placebo ARB Kumagai K, et al. JACC 2003 Discussant ANTIPAF Angiotensin II Antagonist in Paroxysmal Atrial Fibrillation Trial
More informationClinical impact of practice registers in Bourgogne and Rhône Alpes
Clinical impact of practice registers in Bourgogne and Rhône Alpes Dr Yannick Béjot The Dijon Stroke Registry EA4184, University Hospital and Medical School of Dijon, France Dr Carlos El KHOURY c.elkhoury@ch-vienne.fr
More informationSHOULD A REGIONAL STEMI CENTRE ONLY OFFER PRIMARY PCI?
SHOULD A REGIONAL STEMI CENTRE ONLY OFFER PRIMARY PCI? Kurt Huber, MD 3 Department of Internal Medicine, Cardiology and Intensive Care Medicine, Wilhelminenhospital, Vienna, Austria Disclosures DISCLOSURE
More informationGiancarlo Comi, M.D. On Behalf of the MS-LAQ-301 (ALLEGRO) Study Group. Assessment of oral laquinimod in preventing progression of Multiple Sclerosis
COMPARISON OF EARLY AND DELAYED ORAL LAQUINIMOD IN PATIENTS WITH RELAPSING- REMITTING MULTIPLE SCLEROSIS: EFFECTS ON DISABILITY PROGRESSION AT 36 MONTHS IN THE ALLEGRO TRIAL Giancarlo Comi, M.D. On Behalf
More informationIndustry Relationships and Institutional Affiliations
Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated daily statin: results from the ODYSSEY COMBO II study Christopher
More informationSignificant Relationships
Opening Large Vessels During Acute Ischemic Stroke Significant Relationships Wade S Smith, MD, PhD Director UCSF Neurovascular Service Professor of Neurology Daryl R Gress Endowed Chair of Neurocritical
More informationESC Heart & Brain Workshop
Supported by Bayer, Bristol-Myers Squibb and Pfizer Alliance, Boehringer Ingelheim, Daiichi Sankyo Europe GmbH and Medtronic in the form of educational grants. The scientific programme has not been influenced
More informationWhy Should We Treat PFO?
Why Should We Treat PFO? SCAI Interventional Cardiology Fellows Course December 7, 2012 Jonathan Tobis, MD Director of Interventional Cardiology UCLA Disclosures Jonathan Tobis, MD 1. A Principal Investigator
More informationManagement of LDL as a Risk Factor. Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil
Management of LDL as a Risk Factor Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Consulting for: Merck, Astra Zeneca, ISIS- Genzyme, Novo-Nordisk, BMS, Pfizer,
More informationStarting or Resuming Anticoagulation or Antiplatelet Therapy after ICH: A Neurology Perspective
Starting or Resuming Anticoagulation or Antiplatelet Therapy after ICH: A Neurology Perspective Cathy Sila MD George M Humphrey II Professor and Vice Chair of Neurology Director, Comprehensive Stroke Center
More informationPRESCRIBING HORMONAL CONTRACEPTIVES TO WOMEN WITH MIGRAINE (CON) Disclosures. Objectives/Discussion Points 6/2/2017
PRESCRIBING HORMONAL CONTRACEPTIVES TO WOMEN WITH MIGRAINE (CON) Gretchen E. Tietjen, MD Department of Neurology University of Toledo Disclosures Advisory Boards: Eli Lilly, Dr. Reddy s Common Stock: J&J,
More informationDirect oral anticoagulants for Embolic Strokes of Undetermined Source? George Ntaios University of Thessaly, Larissa/Greece
Direct oral anticoagulants for Embolic Strokes of Undetermined Source? George Ntaios University of Thessaly, Larissa/Greece Disclosures Scholarships: European Stroke Organization; Hellenic Society of Atherosclerosis.
More informationTrue cryptogenic stroke
True cryptogenic stroke Arne Lindgren, MD, PhD Dept of Clinical Sciences Lund, Neurology, Lund University Dept of Neurology and Rehabilitation Medicine Skåne University Hospital Lund, Sweden Disclosures
More informationCLOSE. Closure of Patent Foramen Ovale, Oral anticoagulants or Antiplatelet Therapy to Prevent Stroke Recurrence
CLOSE Closure of Patent Foramen Ovale, Oral anticoagulants or Antiplatelet Therapy to Prevent Stroke Recurrence Guillaume TURC, MD, PhD Paris Descartes University Sainte-Anne hospital Paris, France On
More informationSimilar risk of malignancy with insulin glargine and neutral protamine Hagedorn
Letter Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, openlabel study J. Rosenstock 1,2,
More informationNAME CTS AFFILIATION DISCLOSURE UPDATED
NAME CTS AFFILIATION DISCLOSURE UPDATED Darcy Marciniuk (Chair) and Canadian and Canadian COPD Alliance Consultant Fee, Speaker s Bureau, Advisory Committee: AstraZeneca, Boehringer-Ingelheim, Canadian
More informationModified-release dipyridamole combined with aspirin for secondary stroke prevention
For reprint orders, please contact: reprints@futuremedicine.com DRUG EVALUATION Modified-release dipyridamole combined with aspirin for secondary stroke prevention Hans-Christoph Diener University Essen,
More informationASCEND A randomized trial of omega-3 fatty acids (fish oil) versus placebo for primary cardiovascular prevention in 15,480 patients with diabetes
ASCEND A randomized trial of omega-3 fatty acids (fish oil) versus placebo for primary cardiovascular prevention in 15,480 patients with diabetes Jane Armitage and Louise Bowman on behalf of the ASCEND
More informationNicolas Bianchi M.D. May 15th, 2012
Nicolas Bianchi M.D. May 15th, 2012 New concepts in TIA Differential Diagnosis Stroke Syndromes To learn the new definitions and concepts on TIA as a condition of high risk for stroke. To recognize the
More informationESC Heart & Brain Workshop
ESC Heart & Brain Workshop The role of vascular surgeon in stroke prevention Barbara Rantner, MD, PhD, Department of Vascular Surgery, Medical University Innsbruck, Innsbruck, Austria Supported by Bayer,
More informationSex Differences in Stroke Risk and Quality of Life after Stroke
Sex Differences in Stroke Risk and Quality of Life after Stroke Cheryl Bushnell, MD, MHS Associate Professor of Neurology Director, WFB Stroke Center Disclosures Research funding from: World Federation
More informationWith the increasing use of MRI, cerebral white matter
Telmisartan on Top of Antihypertensive Treatment Does Not Prevent Progression of Cerebral White Matter Lesions in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) MRI Substudy Ralph
More informationMIGRAINE AFFECTS UP TO
ORIGINAL CONTRIBUTION Scan for Author Video Interview Structural Brain Changes in Inge H. Palm-Meinders, MD Hille Koppen, MD Gisela M. Terwindt, MD, PhD Lenore J. Launer, PhD Junya Konishi, MD Juliette
More informationIndications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute
Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Disclosures Research Support/P.I. Employee Leo Pharma
More informationESC Heart & Brain Workshop
ESC Heart & Brain Workshop Carotid Stenosis - selecting the high risk patients for intervention Alison Halliday, Professor of Vascular Surgery, University of Oxford 20 th January 2018, Prague ESC Workshop
More informationThe HEMORR 2 HAGES, ATRIA and the HAS-BLED bleeding risk prediction scores in anticoagulated atrial fibrillation patients : The AMADEUS study
The HEMORR 2 HAGES, ATRIA and the HAS-BLED bleeding risk prediction scores in anticoagulated atrial fibrillation patients : The AMADEUS study Apostolakis S 1, Lane DA 1, Buller H 2, Lip GY 1 1 University
More informationThe impact of antiretroviral drugs on Cardiovascular Health
The impact of antiretroviral drugs on Cardiovascular Health José López-Sendón Hospital Universitario La Paz. IdiPaz Madrid. Spain Research grants and honoraria from (research committees, clinical trials,
More informationVague Neurological Conditions
Vague Neurological Conditions Dr. John Lefebre, MD, FRCPC Chief Regional Medical Director Europe, India, South Africa, Middle East and Turkey Canada 2014 2 3 4 Agenda Dr. John Lefebre, M.D., FRCPC 1. TIA
More informationCurrent Updates & Challenges In Managing Diabetes in CVD
Current Updates & Challenges In Managing Diabetes in CVD Preventive Cardiovascular Conference 2016 Instituit Jantung Negara 12 th November 2016 Nor Azmi Kamaruddin Diabetes Clinic Department of Medicine
More informationSecondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012
Secondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012 Professor Dan Atar Head, Dept. of Cardiology Councillor of the ESC,
More informationComorbidities of migraine
Comorbidities of migraine Jasna Zidverc Trajković Headache center Comorbidity is greater than coincidental association of two (or more) conditions in the same individual. Feinstein 1963 Migraine has been
More informationPBS Growth. The changing composition of the PBS. PBS Top 10 drugs in transition. Shifting sands for industry as generic volume soars
PBS Growth The changing composition of the PBS PBS Top 10 drugs in transition Shifting sands for industry as generic volume soars The under co-payment market PBS Update 2014-15 Growth in PBS spending was
More informationMMS/Mass Coalition Program, Nov. 4, 2008 Patients with AF: Who Should be on Warfarin?
MMS/Mass Coalition Program, Nov. 4, 2008 Patients with AF: Who Should be on Warfarin? Daniel E. Singer, MD Massachusetts General Hospital Harvard Medical School 1 Speaker Disclosure Information DISCLOSURE
More informationReversible cerebral vasoconstriction syndrome with concurrent bilateral carotid artery dissection
Brief Report Reversible cerebral vasoconstriction syndrome with concurrent bilateral carotid artery dissection Cephalalgia 33(7) 491 495! International Headache Society 2013 Reprints and permissions: sagepub.co.uk/journalspermissions.nav
More informationA Clinical Context Report
Stroke Prevention in Atrial Fibrillation An Expert Commentary With Kenneth W. Mahaffey, MD A Clinical Context Report Stroke Prevention in Atrial Fibrillation Expert Commentary Jointly Sponsored by: and
More informationCryptogenic Strokes: Evaluation and Management
Cryptogenic Strokes: Evaluation and Management 77 yo man with hypertension and hyperlipidemia developed onset of left hemiparesis and right gaze preference, last seen normal at 10:00 AM Brought to ZSFG
More informationCGRP, MONOCLONAL ANTIBODIES AND SMALL MOLECULES (-GEPANTS)
CGRP, MONOCLONAL ANTIBODIES AND SMALL MOLECULES (-GEPANTS) Hans-Christoph Diener Senior Professor of Clinical Neurosciences University Duisburg-Essen Germany CGRP, Monoclonal Antibodies and Small Molecules
More informationThe Strategic Reperfusion Early After STEMI study Implications for clinical practice
The Strategic Reperfusion Early After STEMI study Implications for clinical practice Robert C. Welsh, MD, FRCPC Associate Professor of Medicine Director, Adult Cardiac Catheterization and Interventional
More informationMyocardial Injury after Noncardiac Surgery (MINS): What is it and what can we do to help patients suffering this event? PJ Devereaux, MD, PhD
Myocardial Injury after Noncardiac Surgery (MINS): What is it and what can we do to help patients suffering this event? PJ Devereaux, MD, PhD Disclosure Member of research group with policy of not accepting
More informationSickKids Research Institute: List of Funders
SickKids Research Institute: List of Funders 2009-2010 Agency Funding $ Agency Funding $ 3M Pharmaceuticals 2,901 International Council on Amino Acid Science 80,800 Abbott Diagnostics 6,639 International
More informationPatent Foramen Ovale: Diagnosis and Treatment
Patent Foramen Ovale: Diagnosis and Treatment Anthony DeMaria Judy and Jack White Chair in Cardiology University of California, San Diego At one time or another a Grantee, Sponsored Speaker or Ad-hoc Consultant
More informationWhat s New in the AF Guidelines
Impact on New AF Guidelines on Heart Failure Management Gothenburg - May 22 nd 2011 Europace (2010) 12, 1360-420 http://europace.oxfordjournals.org JACC (2011) 57, 223-42 http://www.cardiosource.org What
More informationDecline in CV-Mortality
Lipids id 2013 What s Changed? Christopher Granger, MD Disclosure Research contracts: AstraZeneca, GSK, Merck, Sanofi- Aventis, BMS, Pfizer, The Medicines Company, Medtronic Foundation, and Boehringer
More informationFaculty Disclosures. Learning Objectives
WWW.AMERICANHEADACHESOCIETY.ORG Pathophysiology Content developed by: Andrew C. Charles, MD, FAHS, Peter J. Goadsby, MD, PhD, FAHS Donna Gutterman, PharmD Faculty Disclosures ANDREW C. CHARLES, MD, FAHS
More informationWhy is Earlier and More Aggressive Treatment of T2 Diabetes Better?
Blood glucose (mmol/l) Why is Earlier and More Aggressive Treatment of T2 Diabetes Better? Disclosures Dr Kennedy has provided CME, been on advisory boards or received travel or conference support from:
More informationCURRICULUM VITAE Intern in Medicine, Beth Israel Hospital, Harvard Medical School, Boston, MA
Bruce D. Kohrman, M.D. 12305 SW 69 th Place Miami, Florida 33156 Telephone: (305) 903-8678 Fax: (305) 661-1672 CURRICULUM VITAE EDUCATION 1977 - B.S. Stanford University, Stanford, CA 1982 - M.D. Case
More informationAtrial Fibrillation. Alan Bell, MD, CCFP. Staff Physician, Humber River Regional Hospital. University of Toronto
Pearls in Thrombosis 1 Atrial Fibrillation Alan Bell, MD, CCFP Staff Physician, Humber River Regional Hospital Assistant tprofessor, Department tof Family and Community Mdii Medicine University of Toronto
More informationImproving Door-to-Needle Times in Acute Ischemic Stroke: Principal Results from the Target: Stroke Initiative
Improving Door-to-Needle Times in Acute Ischemic Stroke: Principal Results from the Target: Stroke Initiative Gregg C. Fonarow MD, Xin Zhao MS, Eric E. Smith MD, MPH, Jeffrey L. Saver MD, Mathew J. Reeves
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/44385 holds various files of this Leiden University dissertation. Author: Ayata, C. Title: Spreading depolarizations : the missing link between mirgraine
More informationAcute and chronic treatments
21st Annual Meeting of the Swiss Stroke Society Lausanne, 11 January 2018 Vasculitis and stroke : Acute and chronic treatments Pr Mathieu ZUBER Service de Neurologie et NeuroVasculaire Groupe Hospitalier
More informationVenous thrombosis in unusual sites
Venous thrombosis in unusual sites Walter Ageno Department of Medicine and Surgery University of Insubria Varese Italy Disclosures Employment Research support Scientific advisory board Consultancy Speakers
More informationThiazide or Thiazide Like? Choosing Wisely Academic Detailing Conference Digby Pines October 12-14
Thiazide or Thiazide Like? Choosing Wisely Academic Detailing Conference Digby Pines October 12-14 Disclosures Pam McLean-Veysey, Team Leader Drug Evaluation Unit DEU funded by the Drug Evaluation Alliance
More information